Phuturdex › Diseases › Central nervous system neoplasm
Drugs in development · updated 30 October 2026
Central nervous system neoplasm: drugs in development
As of 30 October 2026 there are 44 active clinical trials (recruiting or ongoing, phases I–III) on 70 drugs for central nervous system neoplasm. 19 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| BCB-276 | II | 1 | NCT07680439 |
| EntinostatEnitinostat | I–II | 1 | NCT03838042 |
| Gadolinium | II | 1 | NCT03270059 |
| LMP744Topoisomerase-1 Inhibitor LMP744 | I–II | 1 | NCT07416188 |
| NEO212 Oral Capsule | I–II | 1 | NCT06047379 |
| PaxalisibGDC-0084 | I–II | 1 | NCT06208657 |
| SamotolisibLY3023414 | II | 1 | NCT03155620 |
| Tipifarnib | II | 1 | NCT03155620 |
| Ulixertinib | II | 1 | NCT03155620 |
| ONC206 | I | 2 | NCT04541082 |
| 177Lu-DOTATOCLutetium Lu 177-Edotreotide | I | 1 | NCT06441331 |
| ABBV-706 | I | 1 | NCT05599984 |
| BudigalimabABBV-181 | I | 1 | NCT05599984 |
| G207 | I | 1 | NCT03911388 |
| LY3410738 | I | 1 | NCT04521686 |
| NEO100 | I | 1 | NCT06357377 |
| PHST001 | I | 1 | NCT06840886 |
| SavolitinibAZD6094 | I | 1 | NCT03598244 |
| SGT-53 | Early I | 1 | NCT07017816 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| TemozolomideTemodal, Temodar | III | 5 | NCT00978458 |
| LomustineCCNU, Gleostine® | III | 1 | NCT00887146 |
| ProcarbazineMatulane® | III | 1 | NCT00887146 |
| VincristineVincristin, Oncovin [vincristine] | III | 1 | NCT00887146 |
| CarboplatinCarboplatine, Paraplatin | I–II | 3 | NCT06047379 |
| CyclophosphamideCyclophosphamid, Cytoxan | II | 3 | NCT04792489 |
| LarotrectinibBAY2757556, Vitrakvi® | II | 3 | NCT03155620 |
| NivolumabOpdivo, ONO-4538 | I–II | 3 | NCT06047379 |
| SelpercatinibLOXO-292, Retevmo® | I–II | 3 | NCT03157128 |
| CabozantinibResniben®, Cabometyx® | II | 2 | NCT02867592 |
| EnsartinibX-396, Ensatinib | II | 2 | NCT03213652 |
| EntrectinibRozlytrek® | I–II | 2 | NCT02650401 |
| ErdafitinibBalversa® | II | 2 | NCT03210714 |
| EtoposideAvopef®, Etopophos Preservative Free® | II | 2 | NCT06528691 |
| FludarabineFludara, FLUDARABIN | II | 2 | NCT04792489 |
Sorted by most advanced phase and number of active trials. Showing 15 of 51 drugs.
All 70 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Brain Neoplasms 190 drugs
- Glioma 184 drugs
- Glioblastoma 245 drugs
- Non-small-cell lung carcinoma 726 drugs
- Meningioma 33 drugs
- Meningeal carcinomatosis 28 drugs
- Diffuse Intrinsic Pontine Glioma 40 drugs
- Breast neoplasm 593 drugs
- Melanoma 352 drugs
- Lung neoplasm 348 drugs
- Neoplasm 671 drugs
- Medulloblastoma 77 drugs
Broader categories
- Nervous System Diseases 39 drugs
- Nervous system neoplasm 4 drugs
- Neoplasm 671 drugs
- Glandular and epithelial neoplasm 12 drugs
- Nerve tissue neoplasm 4 drugs
- Neuroectodermal tumor 3 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D016543 “Central Nervous System Neoplasms”.